Organon Pharma Indonesia Tbk. vs Sumber Mas Konstruksi Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Sumber Mas Konstruksi Tbk. trades at Rp106 (market cap 132.82B, 1.51M 24h volume). The key difference: Sumber Mas Konstruksi Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| SCPI | SMKM | |
|---|---|---|
Market Cap | 104.4B | 132.82B |
Volume | — | 1.51M |
Lot | — | 15.11K |
Turnover | — | 156.63M |
Average Price | — | 103.68 |
Value | — | 156.63M |
Indicative Equilibrium Price | — | 106 |
Indicative Equilibrium Volume | — | 1 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Sumber Mas Konstruksi Tbk ("Company") formerly PT Rubenindo Artha Subur was established based on the Notarial Deed of E. Sianipar, S.H., No. 07 dated February 04, 1981.
Read more on SMKM →